Business Context and Reporting Period
Company: Profusa, Inc. (PFSA)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Profusa is a clinical-stage digital health company developing biosensing solutions for real-time biochemistry monitoring. Its primary products are Lumee Oxygen (CE approved in Europe for wound care/critical limb ischemia; seeking FDA approval) and Lumee Glucose (in clinical trials for continuous glucose monitoring). The company completed a reverse recapitalization with NorthView Acquisition Corp. on July 11, 2025, and effected a 1-for-75 reverse stock split on February 9, 2026.
Key Financial Metrics
| Metric | 2025 (Actual) | 2024 (Actual) |
|---|---|---|
| Revenue | $0 | $100,000 (Government Grants) |
| Net Loss | $(35.8) million | $(9.2) million |
| Operating Expenses | $27.7 million | $4.6 million |
| Cash and Cash Equivalents | $1.8 million | $0.2 million |
| Working Capital Deficit | $(18.5) million | Not explicitly stated |
| Accumulated Deficit | $(160.8) million | $(125.0) million |
| Debt Obligations (Current) | $6.6 million | $57.1 million (Total Liabilities) |
Note: All share and per-share data has been retroactively adjusted for the 1-for-75 reverse stock split.
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped to zero in 2025 compared to $100,000 in 2024, as the company focused on closing the Business Combination rather than recognizing grant revenue.
- Expense Surge: General and Administrative (G&A) expenses increased by 732% to $24.9 million, driven primarily by $14.5 million in transaction closing costs related to the merger. R&D expenses increased 74% to $2.8 million due to higher regulatory and CRO costs.
- Net Loss Expansion: Net loss increased by 288% to $35.8 million, exacerbated by a $3.4 million loss on the change in fair value of convertible notes and $2.6 million in financing costs.
- Capital Structure: The company raised $19.8 million in financing activities in 2025 (vs. $2.1 million in 2024) via PIPE investments and an Equity Line of Credit (ELOC). Significant debt was converted to equity upon the merger closing.
Guidance, Outlook, and Risks
Outlook and Guidance
- Commercialization: Plans to launch Lumee Oxygen in Europe in early 2026 and seek FDA approval for the U.S. launch in late 2026. Lumee Glucose regulatory submission is expected in early 2026.
- Liquidity Needs: Management estimates near-term capital requirements through December 31, 2026, to be approximately $14.5 million to support R&D, manufacturing, and commercialization.
- Strategic Partnerships: Entered a license agreement with Mayo Clinic (Feb 2026) and a non-binding LOI to acquire Bio Insights assets for $30 million in equity (March 2026).
Material Risks and Contingencies
- Going Concern: The filing includes an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern due to recurring losses and working capital deficits. Additional financing is required.
- Nasdaq Delisting: The company failed to meet Nasdaq Global Market listing requirements (Minimum Bid Price and Market Value of Listed Securities). A delisting hearing is scheduled for April 21, 2026, though the action has been stayed pending appeal.
- Regulatory Approval: No products are approved for commercial sale in the U.S. Failure to obtain FDA clearance for Lumee Oxygen or Lumee Glucose would severely impact the business model.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting, specifically regarding segregation of duties and valuation of financial instruments.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $1.8 million cash balance against the estimated $14.5 million requirement for 2026 operations.
- Nasdaq Status: Monitor the outcome of the April 21, 2026, Nasdaq Hearings Panel regarding potential delisting.
- Debt Conversion: Review the terms of the Ascent PIPE Notes and ELOC, specifically the conversion prices and potential dilution (e.g., floor prices adjusted post-split).
- Regulatory Milestones: Track the timeline for FDA submission of Lumee Oxygen (late 2026) and Lumee Glucose (early 2026) to assess revenue generation feasibility.
- Internal Controls: Assess the remediation plan for the identified material weaknesses in financial reporting.